Patient ID and Activation

Ambit goes beyond the scope of traditional patient identification to focus on improving the rate at which patient leads are qualified and connected to relevant solutions and next steps

Ambit works within the dimensions of the patient funnel to optimize the process by which patients are activated and converted to appropriate treatment and/or clinical trials. To optimize the patient funnel, the Ambit Patient ID team has two key offerings:

  1. Patient Funnel Optimization to measure and improve the effectiveness of ongoing patient identification activities
    • Activity Log: What activities have been done / planned to identify patients
    • Measure Effectiveness: What is the expected v. actual yield of these activities (including cost / patient)
    • Leverage / Leakage Points: How can current activities be optimized to mitigate leaks
    • Roadmap: Provide a plan of patient ID initiatives across all levels of the patient funnel through a co-created roadmap with the client team
  2. Patient ID Implementation Support to actualize patient ID plans for improved return on investment
    • Claims-based / EMR lead identification & validation
    • COE / Specialty Center Engagement & Partnership
    • Adjacent Patient Advocacy Partnerships
    • Patient Registry / Biobank Screening Partnerships
    • Genetic Counseling Partner Screening Study
    • Development of Landing Page & Qualification / Consent Tool
    • Genetic Counseling & Testing through telehealth partner
    • Ambit Ambassador Patient Engagement to facilitate conversion

learn more

Contact us to learn more about how Ambit can help you maximize the productivity of your patient identification workflow.

join the patient id and activation team

meet the patient id and activation team

Deirdre comes from a background in life sciences consulting, as well as bench research in the field of stem cell and regenerative biology. She is a published author in the field, including on the involvement of the STMN2 gene in ALS, which has resulted in clinical stage trials targeting the mechanism. Her training in stem cell biology and gene editing contributes to her interest in the field of drug discovery, especially in rare and genetic diseases. She enjoys collaborating with pharmaceutical clients to understand their needs in patient identification, and how Ambit’s strengths may help to form a productive partnership. She strategizes with the team on how Ambit’s capabilities may translate to solve broader problems in rare disease, including patient diagnosis. She currently resides in Boston, MA after receiving her Bachelor’s in Human Developmental and Regenerative Biology from Harvard.
Deirdre Potter
Biopharma Strategy and Operations Senior Analyst
Elizabeth brings extensive healthcare and operational experience to Ambit with three successful startups, 20 years leading consulting firms, and decades of patient and provider market research. She directs special projects with patient advocacy partners and serves as a board member.
Elizabeth Rountree

Co-Founder and Board Member

Hannah brings a detail oriented and analytical perspective to the team. Her work on the platform has involved implementing, tracking, and optimizing workflows. Hannah is always eager to jump on any project where she can make an impact. She is passionate about learning from others and continuing to improve and expand her skills. Prior to joining Ambit, Hannah received her BBA from the University of Michigan Ross School of Business, where she also competed as an NCAA Division I golfer. Her experience as a student athlete helped prepare her for the fast-paced and exciting environment at Ambit. She was born and raised in Falmouth, MA but resides now in Ann Arbor, Michigan with her fiancé and dog Norman.
Hannah Ghelfi
Senior Analyst
Jenn D’Arcangelo has 10+ years of experience in life sciences research and consulting. Jenn received her Ph.D. in molecular and cellular biology from Columbia University where she first became acquainted with rare diseases, studying molecular pathways in Cystic Fibrosis models. Transitioning into biopharma consulting, Jenn has garnered a breadth of experience across specialty and rare disease supporting client needs at every stage of the product development life-cycle. At Ambit, Jenn is leveraging her expertise to support the commercial business in delivering the highest quality services and products to our biopharma partners. She is equally passionate about how our work will provide patients and families living with a rare disease a faster, easier path to diagnosis and ultimately life-changing treatments.
Jennifer D'Arcangelo
VP Commercial Operations
Laney has eight years of experience in consulting and biopharma, including a consumer health data startup, and an EHR company. This experience gives her a deep understanding of corporate strategy, patient dynamics and an ability to use data to solve problems. She leads AmbitCare in support of patients, caregivers, and healthcare providers.
Laney Forton

Co-Founder and Vice President

Rachel brings an analytical mindset to the team and strives to make data-driven decisions. She works with the platform team to develop processes for patient identification that clients can use to advance research and treatment. Prior to joining Ambit, Rachel completed her master’s at Duke’s Fuqua School of Business while working a full-time job. This experience provided Rachel the necessary business fundamentals, industry context, and advanced data analytics skills needed for decision-making in health care markets. Rachel brings a dedicated work-ethic to the team and enjoys collaborating with others to create comprehensive solutions for complex problems. She holds a BA in biology from the University of Virginia and a MS in quantitative management from Duke University. She was born and raised in Virginia and currently lives there with her fiancé, Ryan, and their 2 dogs.
Rachel Ritter